AML Hub

De: Scientific Education Support
Escúchala gratis

  • Resumen

  • The AML Hub is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education on acute myeloid leukemia (AML). Our aim is to enhance knowledge in AML through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.

    Hosted on Acast. See acast.com/privacy for more information.
    Scientific Education Support
    Más Menos
Más Menos
Episodios
  • “How I treat” a patient with DNMT3A-mutated AML in remission post intensive chemotherapy

    “How I treat” a patient with DNMT3A-mutated AML in remission post intensive chemotherapy
    Oct 3 2024

    The AML Hub was pleased to speak with Cristina Papayannidis, Universitaria di Bologna, Bologna, IT. We asked, How do you treat a patient with DNMT3A-mutated acute myeloid leukemia (AML) in remission post intensive chemotherapy?

    This educational resource is independently supported by Bristol Myers Squibb. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.

    Hosted on Acast. See acast.com/privacy for more information.
    Más Menos
    6 m
  • CPX-351 as first-line treatment in AML: Real-world data

    CPX-351 as first-line treatment in AML: Real-world data
    Sep 30 2024
    Here, we summarize five real-world studies presented at EHA 2024 on real-world outcomes of patients with AML who received CPX-351 as a first-line treatment.

    Hosted on Acast. See acast.com/privacy for more information.
    Más Menos
    17 m
  • What is the impact of the 5th WHO classification and ICC of AML on diagnosis and treatment of high-risk AML​?

    What is the impact of the 5th WHO classification and ICC of AML on diagnosis and treatment of high-risk AML​?
    Sep 17 2024

    The AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What is the impact of the 5th World Health Organization (WHO) classification and International Consensus Classification (ICC) of AML on diagnosis and treatment of high-risk acute myeloid leukemia (HR AML)​?

    In this interview, Roboz walks through the changes in the classification criteria for AML over the last 50 years, highlighting the implications of these changes and the lack of consensus on the diagnosis and management strategies for patients. Roboz goes on to discuss both classification and prognostic risk stratification tools to aid in the development of management strategies, including in HR AML, and concludes by highlighting the importance of considering patient preferences and health when making clinical decisions.

    This educational resource is independently supported by Jazz Pharmaceuticals. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.

    Hosted on Acast. See acast.com/privacy for more information.
    Más Menos
    13 m
adbl_web_global_use_to_activate_webcro768_stickypopup

Lo que los oyentes dicen sobre AML Hub

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles